Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
Reduced dorsal prefrontal gray matter after chronic ketamine use
Our injections are given by a licensed and certified provider who is available to answer any questions you have about your injection
For more on managing medication adjustment, our article on how to ease semaglutide side effects is worth a look
Pendulum Product Comparison The comparison is not a ranking from weakest to strongest
GLP1 receptors are also found in brain regions involved in appetite, reward, motivation, stress response, and metabolic regulation
US$ 25.76
US$ 28.39
US$ 29.33
US$ 28.90
US$ 23.30
US$ 22.78
